Human medicines European public assessment report (EPAR): Benlysta, belimumab, Date of authorisation: 13/07/2011, Revision: 37, Status: Authorised

Veterinary medicines European public assessment report (EPAR): Emevet, maropitant, Status: Authorised

EMA Cancer Medicines Forum (CMF) meeting with industry stakeholders on cancer treatment optimisation, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 November 2025, 13:30 (CET) to 14 November 2025, 17:30 (CET)

Search tips

Azacitidine product-specific bioequivalence guidance

Overview of comments received on the “HMA/EMA guidance document on the identification of personal data and commercially confidential information within the structure of the marketing authorisation application (MAA) dossier” - public consultation

Aprepitant product-specific bioequivalence guidance

Human medicines European public assessment report (EPAR): Nemluvio, nemolizumab, Date of authorisation: 12/02/2025, Revision: 2, Status: Authorised

Vortioxetine hydrobromide / vortioxetine lactate product-specific bioequivalence guidance

Zonisamide product-specific bioequivalence guidance